MarketPulse

ARVO 2026

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Oculis Holding Ag

Oculis Eyes DME Market With First Eye Drop Therapy as ARVO Data Show Unmet Need

Oculis' DME AWARE study confirms expert demand for non-invasive treatment; OCS-01 eye drops target June 2026 Phase 3 results as potential first-in-class DME therapy.
OCSOCSAWdiabetic macular edemanon-invasive treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Oculis Holding Ag

Oculis to Showcase Late-Stage Pipeline at ARVO 2026 Amid Key DME Trial Readout

Oculis will present its ophthalmology pipeline at ARVO 2026, with Phase 3 results for lead DME candidate OCS-01 expected in June.
OCSOCSAWclinical trialsdiabetic macular edema
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis to Showcase Late-Stage Pipeline at ARVO 2026 as OCS-01 Phase 3 Data Nears

Oculis to present advancing ophthalmology pipeline at ARVO 2026, with Phase 3 OCS-01 DME results expected June 2026.
OCSOCSAWPhase 3 clinical trialdiabetic macular edema
GlobeNewswire Inc.GlobeNewswire Inc.··Na

OKYO Pharma's Neuropathic Eye Pain Therapy Earns ARVO 2026 Presentation Slot

OKYO Pharma's urcosimod earns ARVO 2026 presentation slot for neuropathic eye pain therapy. Phase 2a data shows pain reduction and quality-of-life improvements; Phase 2b/3 trial planned for 2026.
OKYOclinical trial resultsneuropathic corneal pain